A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma

James W Jakub, Travis E. Grotz, Philip Jordan, Ewan Hunter, Mark Pittelkow, Aroul Ramadass, Alexandre Akoulitchev, Svetomir Nenad Markovic

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Prognosis is markedly improved when melanoma is diagnosed early. Improved methods are needed for earlier detection and screening. We hypothesized that epigenetic analysis of blood samples could discriminate patients with melanoma from patients with other cutaneous lesions and from healthy volunteers. After institutional review board approval and consent, whole blood was obtained from 59 patients with melanoma, 20 patients with other skin cancers, 20 patients with benign skin conditions, and 20 healthy volunteers. Fifteen conformation biomarkers from five gene loci were analyzed on chromatin with the EpiSwitch technology using a modified chromatin conformation capture assay. Differentiation between patients with melanoma and those with nonmelanoma skin cancers was correct 85% of the time, resulting in a sensitivity of 88% and a specificity of 82%. Differentiation of patients with melanoma from healthy controls was correct 80% of the time, resulting in a sensitivity of 85% and a specificity of 75%. The noninvasive test was more accurate in early-stage melanoma (1/10 and 1/16 stage I and stage II patients were misclassified, respectively) and became less accurate with more advanced disease (3/14 and 4/19 stage III and IV patients were misclassified, respectively). We report the results of a noninvasive test using chromosomal aberrations and epigenetic changes identified in peripheral blood that, in this pilot study, distinguished patients with early-stage melanoma from other cohorts.

Original languageEnglish (US)
Pages (from-to)406-411
Number of pages6
JournalMelanoma Research
Volume25
Issue number5
DOIs
StatePublished - Sep 18 2015

Fingerprint

Epigenomics
Chromosome Aberrations
Melanoma
Skin Neoplasms
Chromatin
Healthy Volunteers
Skin
Research Ethics Committees
Biomarkers
Technology

Keywords

  • blood test
  • chromatin conformational signatures
  • circulating tumor cells
  • epigenetics
  • melanoma
  • screening

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Dermatology

Cite this

A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma. / Jakub, James W; Grotz, Travis E.; Jordan, Philip; Hunter, Ewan; Pittelkow, Mark; Ramadass, Aroul; Akoulitchev, Alexandre; Markovic, Svetomir Nenad.

In: Melanoma Research, Vol. 25, No. 5, 18.09.2015, p. 406-411.

Research output: Contribution to journalArticle

Jakub, James W ; Grotz, Travis E. ; Jordan, Philip ; Hunter, Ewan ; Pittelkow, Mark ; Ramadass, Aroul ; Akoulitchev, Alexandre ; Markovic, Svetomir Nenad. / A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma. In: Melanoma Research. 2015 ; Vol. 25, No. 5. pp. 406-411.
@article{2451ef193f2e4b1aa7c800f1788b7ae5,
title = "A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma",
abstract = "Prognosis is markedly improved when melanoma is diagnosed early. Improved methods are needed for earlier detection and screening. We hypothesized that epigenetic analysis of blood samples could discriminate patients with melanoma from patients with other cutaneous lesions and from healthy volunteers. After institutional review board approval and consent, whole blood was obtained from 59 patients with melanoma, 20 patients with other skin cancers, 20 patients with benign skin conditions, and 20 healthy volunteers. Fifteen conformation biomarkers from five gene loci were analyzed on chromatin with the EpiSwitch technology using a modified chromatin conformation capture assay. Differentiation between patients with melanoma and those with nonmelanoma skin cancers was correct 85{\%} of the time, resulting in a sensitivity of 88{\%} and a specificity of 82{\%}. Differentiation of patients with melanoma from healthy controls was correct 80{\%} of the time, resulting in a sensitivity of 85{\%} and a specificity of 75{\%}. The noninvasive test was more accurate in early-stage melanoma (1/10 and 1/16 stage I and stage II patients were misclassified, respectively) and became less accurate with more advanced disease (3/14 and 4/19 stage III and IV patients were misclassified, respectively). We report the results of a noninvasive test using chromosomal aberrations and epigenetic changes identified in peripheral blood that, in this pilot study, distinguished patients with early-stage melanoma from other cohorts.",
keywords = "blood test, chromatin conformational signatures, circulating tumor cells, epigenetics, melanoma, screening",
author = "Jakub, {James W} and Grotz, {Travis E.} and Philip Jordan and Ewan Hunter and Mark Pittelkow and Aroul Ramadass and Alexandre Akoulitchev and Markovic, {Svetomir Nenad}",
year = "2015",
month = "9",
day = "18",
doi = "10.1097/CMR.0000000000000182",
language = "English (US)",
volume = "25",
pages = "406--411",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma

AU - Jakub, James W

AU - Grotz, Travis E.

AU - Jordan, Philip

AU - Hunter, Ewan

AU - Pittelkow, Mark

AU - Ramadass, Aroul

AU - Akoulitchev, Alexandre

AU - Markovic, Svetomir Nenad

PY - 2015/9/18

Y1 - 2015/9/18

N2 - Prognosis is markedly improved when melanoma is diagnosed early. Improved methods are needed for earlier detection and screening. We hypothesized that epigenetic analysis of blood samples could discriminate patients with melanoma from patients with other cutaneous lesions and from healthy volunteers. After institutional review board approval and consent, whole blood was obtained from 59 patients with melanoma, 20 patients with other skin cancers, 20 patients with benign skin conditions, and 20 healthy volunteers. Fifteen conformation biomarkers from five gene loci were analyzed on chromatin with the EpiSwitch technology using a modified chromatin conformation capture assay. Differentiation between patients with melanoma and those with nonmelanoma skin cancers was correct 85% of the time, resulting in a sensitivity of 88% and a specificity of 82%. Differentiation of patients with melanoma from healthy controls was correct 80% of the time, resulting in a sensitivity of 85% and a specificity of 75%. The noninvasive test was more accurate in early-stage melanoma (1/10 and 1/16 stage I and stage II patients were misclassified, respectively) and became less accurate with more advanced disease (3/14 and 4/19 stage III and IV patients were misclassified, respectively). We report the results of a noninvasive test using chromosomal aberrations and epigenetic changes identified in peripheral blood that, in this pilot study, distinguished patients with early-stage melanoma from other cohorts.

AB - Prognosis is markedly improved when melanoma is diagnosed early. Improved methods are needed for earlier detection and screening. We hypothesized that epigenetic analysis of blood samples could discriminate patients with melanoma from patients with other cutaneous lesions and from healthy volunteers. After institutional review board approval and consent, whole blood was obtained from 59 patients with melanoma, 20 patients with other skin cancers, 20 patients with benign skin conditions, and 20 healthy volunteers. Fifteen conformation biomarkers from five gene loci were analyzed on chromatin with the EpiSwitch technology using a modified chromatin conformation capture assay. Differentiation between patients with melanoma and those with nonmelanoma skin cancers was correct 85% of the time, resulting in a sensitivity of 88% and a specificity of 82%. Differentiation of patients with melanoma from healthy controls was correct 80% of the time, resulting in a sensitivity of 85% and a specificity of 75%. The noninvasive test was more accurate in early-stage melanoma (1/10 and 1/16 stage I and stage II patients were misclassified, respectively) and became less accurate with more advanced disease (3/14 and 4/19 stage III and IV patients were misclassified, respectively). We report the results of a noninvasive test using chromosomal aberrations and epigenetic changes identified in peripheral blood that, in this pilot study, distinguished patients with early-stage melanoma from other cohorts.

KW - blood test

KW - chromatin conformational signatures

KW - circulating tumor cells

KW - epigenetics

KW - melanoma

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=84941764277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941764277&partnerID=8YFLogxK

U2 - 10.1097/CMR.0000000000000182

DO - 10.1097/CMR.0000000000000182

M3 - Article

VL - 25

SP - 406

EP - 411

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 5

ER -